Journal article
Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis
Abstract
OBJECTIVE: Cases of inflammatory bowel disease (IBD) during treatment with interleukin (IL)-17 antagonists have been reported from trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The aim of this study was to assess the overall risk for development of IBD due to IL-17 inhibition.
DESIGN: Systematic review and meta-analysis of studies conducted 2010-2018 of treatment with IL-17 antagonists in patients with psoriasis, …
Authors
Burisch J; Eigner W; Schreiber S; Aletaha D; Weninger W; Trauner M; Reinisch W; Narula N
Journal
PLOS ONE, Vol. 15, No. 5,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.pone.0233781
ISSN
1932-6203